Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026)
Inhibikase Therapeutics (IKT) reported Non Operating Investment Income of -$48095.0 for Q1 2026, down 232.56% year-over-year from $36281.0 in Q1 2025, and down 285.04% quarter-over-quarter from $25991.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 5 years of Non Operating Investment Income data on file, last reported at -$48095.0 in Q1 2026.
- Non Operating Investment Income for Q1 2026 came in at -$48095.0, down 232.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$25326.0 (down 3140.34% YoY), and the FY2025 annual result was $59050.0, up 254.89% from the prior year.
- Non Operating Investment Income slipped to -$48095.0 in Q1 2026 per IKT's latest filing, from $25991.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $36281.0 in Q1 2025 and troughed at -$167536.0 in Q2 2023.
- A 5-year average of -$13858.9 and a median of -$234.5 in 2024 frame the typical range for Non Operating Investment Income.
- On a YoY basis, Non Operating Investment Income climbed as much as 1455.29% in 2025 and fell as far as 354.77% in 2025.
- A 5-year view of Non Operating Investment Income shows it stood at $26828.0 in 2022, then slumped by 94.14% to $1571.0 in 2023, then slumped by 2582.62% to -$39002.0 in 2024, then surged by 166.64% to $25991.0 in 2025, then sank by 285.04% to -$48095.0 in 2026.
- Business Quant data shows IKT's Non Operating Investment Income at -$48095.0 in Q1 2026, $25991.0 in Q4 2025, and -$1245.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -48,095.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48,095.00 |
| Mar 31, 2026 | -48,095.00 |
| Dec 31, 2025 | 25,991.00 |
| Dec 31, 2025 | 25,991.00 |
| Sep 30, 2025 | -1,245.00 |
| Sep 30, 2025 | -1,245.00 |
| Jun 30, 2025 | -1,977.00 |
| Jun 30, 2025 | -1,977.00 |
| Mar 31, 2025 | 36,281.00 |
| Mar 31, 2025 | 36,281.00 |
| Dec 31, 2024 | -39,002.00 |
| Dec 31, 2024 | -39,002.00 |
| Sep 30, 2024 | 2,778.00 |
| Sep 30, 2024 | 2,778.00 |
| Jun 30, 2024 | 776.00 |
| Jun 30, 2024 | 776.00 |
| Mar 31, 2024 | -2,677.00 |
| Mar 31, 2024 | -2,677.00 |
| Sep 30, 2023 | 1,571.00 |
| Sep 30, 2023 | 1,571.00 |